PATENT CLAIM ANALYSIS

Application Number: 16403176
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-08
Patent Classification: ["424", "489000"]

Abstract:
Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).

Claim (Index 54):
A single dose pharmaceutical composition for treating bacterial vaginosis in a subject in need thereof comprising a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a particle size in the range of 400 micrometers to about 841 micrometers, and wherein the therapeutically effective amount of secnidazole in the microgranule formulation is an amount of secnidazole that exhibits a time to maximum plasma concentration (Tmax) of about 3 hours to about 4 hours in the subject, wherein the single dose pharmaceutical composition is for oral administration, and wherein secnidazole is the sole drug in the microgranule formulation.

Metadata:
- Claim Count in Document: 146.0
- Percentile: 100.0
- Lexical Diversity: 1.2
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14846505', '16049032', '13472953', '15990010', '13982675']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.747863396008973
- 35 USC 102 Novelty (BERT): 0.7494781240395282
- Combined Prediction Score: 0.7480248688120286
- Mean Citation Score: 462.23057400000016
- Max Citation Score: 835.29974
- Similarity Product: 785.4301944524658

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test